Study to Assess Participant Satisfaction After Jawline and Neck Treatment
← catalyst calendarNCT07794891 · readout ≤ 302 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 4
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-31
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-04 | estimated | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Jawline and Neck Appearance
Interventions
- Drug: OnabotulinumtoxinA
- Device: SKINVIVE
- Device: VOLUX
- Device: VOLUMA
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants With Response of Satisfied or Very Satisfied on Appearance of Neck and Lower Face Questionnaire (ANLFQ): Satisfaction Follow-Up
measured Day 104
Related
ABBV · their whole pipeline · Who in Congress owns ABBV? · Executive-branch trades in ABBV
ABBV's other studiesmost recently updated first
- Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Phase 2/3 · Recruiting
- A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis Phase 3 · Recruiting
- A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer Phase 3 · Recruiting
- A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives Phase 1 · Completed
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma Phase 2/3 · Recruiting
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed